The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.
Cancellation and Refund
Subscriptions renew automatically and future shipments can be cancelled at any time. A prescription product cannot be returned once it has shipped.